Faron Pharmaceuticals

Faron Pharmaceuticals is a Finnish drug discovery and development company headquartered in Turku. Founded in 2003 by a group led by Markku Jalkanen, the company has built its research strategy around controlling inflammatory and immune responses involved in acute organ injury, vascular damage, respiratory distress, and cancer. Rather than operating as a broad commercial medicines manufacturer, Faron has primarily functioned as a clinical-stage biopharmaceutical developer whose value proposition depends on advancing proprietary drug candidates through clinical development and, where appropriate, toward regulatory approval or partnering. The company’s best-known candidate is Traumakine, an investigational treatment designed for acute respiratory distress syndrome and related severe inflammatory conditions. Its proposed mechanism involves increasing expression of CD73 in the lungs and thereby promoting production of anti-inflammatory adenosine. The intended effect is to reduce vascular leakage and limit the escalation of inflammation associated with acute lung injury. Traumakine entered international clinical development, including phase III planning, after encouraging results in an earlier open-label study. In March 2020, the United States Food and Drug Administration accepted the proposed protocol design for a subsequent Traumakine study. During the COVID-19 pandemic, Traumakine was selected for evaluation in international platform trials, including the World Health Organization Solidarity trial and the REMAP-CAP programme, which investigated potential treatments for serious COVID-19-related illness. Faron’s other principal programme is Clevegen, an anti-Clever-1 antibody intended to alter the immune environment surrounding tumours. The candidate is designed to reduce an immunosuppressive tumour milieu and promote a more immune-stimulating response, representing an approach within cancer immunotherapy. During 2020, Clevegen was being evaluated in phase I/II European clinical trials, with expansion to additional cancer indications and potential development in the United States under consideration. The company identified colorectal, ovarian, liver, and pancreatic cancers among the difficult-to-treat malignancies that could be explored in expanded studies. Faron obtained external support for its programmes during 2020. Business Finland provided a low-interest loan of €2.1 million to support Traumakine manufacturing, while the Cancer IO national research and innovation project received €10 million through Business Finland’s personalised-health programme; Faron’s stated contribution to that project was €800,000. In April 2020, a share placing raised €14 million, providing resources intended in part to broaden Clevegen development. These financing events reflected the capital-intensive nature of clinical-stage biotechnology and the company’s need to fund trials, manufacturing development, and translational research. The company’s securities have been traded in London on AIM and, since December 2019, secondarily in Helsinki on Nasdaq First North Growth Market Finland. Faron has described the Helsinki listing as a way to improve visibility and facilitate access for Scandinavian shareholders. Its public identity is therefore closely linked to its clinical pipeline, financing activities, and specialist focus on immunobiology rather than to a portfolio of marketed consumer medicines. Regulatory status, commercial availability, and ultimate clinical outcomes for the described candidates remain dependent on the results of clinical trials and subsequent regulatory review.

Faron Pharmaceuticals was established in 2003 in Finland by a group led by Markku Jalkanen, who later became and is identified as the company’s chief executive. From its early development, Faron concentrated on drug discovery and clinical programmes addressing inflammatory injury and immune regulation rather than on conventional mass-market pharmaceutical products. Its research themes included acute organ trauma, damage to the vascular system, and the biological processes that cause uncontrolled inflammation. The company’s principal acute-care programme became Traumakine, an investigational therapy for acute respiratory distress syndrome. The programme was based on the idea that increasing pulmonary CD73 expression could increase local production of anti-inflammatory adenosine. By seeking to reduce vascular leakage and inflammatory escalation, the treatment was intended to address important pathological features of acute respiratory distress. After an open-label early-stage study produced encouraging findings, Traumakine progressed into international clinical development and was being prepared for phase III evaluation. In March 2020, the FDA accepted the proposed design for a further study comparing efficacy in patients with acute respiratory distress syndrome. The COVID-19 pandemic expanded the visibility and potential application of the Traumakine programme. In 2020, the candidate was selected for the WHO Solidarity trial and the REMAP-CAP platform, both of which evaluated possible treatments for serious COVID-19-associated illness. Faron also obtained a €2.1 million low-interest loan from Business Finland in June 2020 to support Traumakine manufacturing. This support connected the company’s clinical development work with the practical need to establish production capacity for a potential acute-care medicine. Faron’s second major programme, Clevegen, addressed cancer immunotherapy. Clevegen is an anti-Clever-1 antibody intended to modify the tumour immune environment. The development concept was to shift a tumour from an immune-suppressive state toward one that is more capable of supporting anti-tumour immune activity. During 2020, Clevegen was undergoing phase I/II trials in Europe, including work in bowel cancer and other malignancies. The company indicated that development could be extended to the United States and that expanded studies could examine difficult cancers such as colorectal, ovarian, hepatic, and pancreatic cancer. Faron financed this expansion through a €14 million share placing in April 2020. The company stated that the funds would support enlargement of the Clevegen study and investigation of additional cancer types. In the same period, Faron participated in the Cancer IO national research and innovation project. The project received €10 million from Business Finland’s personalised-health programme, with Faron contributing €800,000. The company also developed its capital-market presence. Faron was listed on London’s Alternative Investment Market and obtained a secondary listing on Nasdaq First North Growth Market Finland in December 2019. Management described the Helsinki listing as a means of increasing visibility and making the shares more accessible to Scandinavian investors. By 2020, Faron’s identity was that of an internationally oriented, Finland-based clinical-stage biotechnology company whose prospects depended on the trial progress, financing, manufacturing, and regulatory development of Traumakine and Clevegen. The available reference material does not establish later clinical outcomes, approvals, commercial launches, or subsequent leadership changes.

• 2020

  FDA accepts proposed Traumakine study design

  [1]Faron Pharmaceuticalsen.wikipedia.org

  The FDA accepted the proposed protocol design for a subsequent Traumakine study in acute respiratory distress syndrome.

• 2020

  Traumakine enters international COVID-19 trial programmes

  [1]Faron Pharmaceuticalsen.wikipedia.org

  Traumakine was selected for the WHO Solidarity trial and REMAP-CAP programme.

• 2020

  Share placing supports Clevegen development

  [1]Faron Pharmaceuticalsen.wikipedia.org

  Faron raised €14 million through a share placing to expand Clevegen research across additional cancer indications.

• 2019

  Secondary Helsinki listing

  [1]Faron Pharmaceuticalsen.wikipedia.org

  Faron obtained a secondary listing on Nasdaq First North Growth Market Finland while retaining its London AIM listing.

• 2003

  Company founded

  [1]Faron Pharmaceuticalsen.wikipedia.org

  Faron Pharmaceuticals was founded in Finland by a group led by Markku Jalkanen.

A clinical-stage biopharmaceutical company focused on immunological mechanisms underlying acute organ injury, vascular leakage, respiratory distress, and cancer.

• Investigational acute-care biopharmaceutical

  Traumakine

  Traumakine is Faron’s investigational treatment for acute respiratory distress syndrome and related severe inflammatory conditions. Its proposed biological action is to increase CD73 expression in the lungs and support production of anti-inflammatory adenosine. The programme was intended to reduce vascular leakage and inflammatory escalation. After an encouraging open-label early-stage study, it advanced into international development and was being prepared for phase III evaluation. In 2020, it was selected for the WHO Solidarity and REMAP-CAP treatment platforms for serious COVID-19-related illness. No approved commercial status is established by the supplied reference material.

• Cancer immunotherapy

  Clevegen

  Clevegen is an anti-Clever-1 antibody developed as an immuno-oncology candidate. Its intended role is to reshape the tumour immune environment by reducing immune suppression and encouraging a more immune-stimulating state. During 2020, the candidate was being studied in phase I/II European clinical trials, including trials involving bowel cancer and other tumour types. Faron described possible expansion into the United States and additional difficult-to-treat cancers, including colorectal, ovarian, hepatic, and pancreatic cancers. The supplied material does not establish regulatory approval or commercial launch.

• 2020

  Advance Traumakine into international platform trialsProduct launch

  Background

  The COVID-19 pandemic created an urgent need to evaluate potential treatments for severe respiratory and inflammatory disease.

  Action taken

  Traumakine was selected for the WHO Solidarity trial and REMAP-CAP programme.

  Aftermath

  The candidate gained access to international platform-trial evaluation, although the supplied material does not report definitive clinical outcomes.

  Source

• 2020

  Expand Clevegen’s cancer development programmeStrategy

  Background

  Faron’s phase I/II Clevegen programme was being evaluated in Europe, and the company identified several additional difficult cancer indications.

  Action taken

  Following a €14 million share placing, Faron planned to broaden Clevegen studies to colorectal, ovarian, hepatic, pancreatic, and other cancers, with possible expansion into the United States.

  Aftermath

  The financing supplied resources for wider clinical development; subsequent trial results are not provided in the reference material.

  Share-placing proceeds. €14 million raised (April 2020)

  Source

• 2020

  Fund Traumakine manufacturingStrategy

  Background

  Clinical development of an acute-care medicine required manufacturing support and production planning.

  Action taken

  Faron accepted a low-interest Business Finland loan to support Traumakine manufacturing.

  Aftermath

  The loan supported manufacturing-related development, but the supplied material does not describe later production scale or commercial supply.

  Business Finland low-interest loan. €2.1 million (June 2020)

  Source

• 2019

  Add a secondary listing in HelsinkiStrategy

  Background

  Faron was already listed on London’s AIM and sought greater visibility and easier share trading for Scandinavian investors.

  Action taken

  The company obtained a secondary listing on Nasdaq First North Growth Market Finland in December 2019.

  Aftermath

  The listing gave Faron an additional Nordic capital-market presence; later effects are not specified in the supplied material.

  Source

1. 1Faron Pharmaceuticalsen.wikipedia.org